Lower Mortality Associated With Adjuvant Corticosteroid Therapy in Non-HIV-Infected Patients With Pneumocystis jirovecii Pneumonia: A Single-Institution Retrospective US Cohort Study.
William MundoLouis Morales-ShnaiderSelam TewahadeEric WagnerSolana ArchuletaMohamed BandaliSindhu ChadalawadaSteven C JohnsonCarlos Franco-ParedesLeland ShapiroAndrés F Henao MartinezPublished in: Open forum infectious diseases (2020)
We found substantial mortality among HIV-negative patients with PJP, and adjuvant corticosteroid use was associated with decreased mortality. Response to corticosteroids is best established in HIV-infected patients, but emerging reports suggest a similar beneficial response in PJP patients without HIV infection. Further prospective studies may establish a more definitive role of the addition of corticosteroids among HIV-negative patients with PJP.
Keyphrases
- antiretroviral therapy
- hiv infected patients
- hiv infected
- hiv positive
- human immunodeficiency virus
- hiv aids
- cardiovascular events
- end stage renal disease
- early stage
- chronic kidney disease
- risk factors
- ejection fraction
- newly diagnosed
- emergency department
- prognostic factors
- peritoneal dialysis
- cardiovascular disease
- type diabetes
- extracorporeal membrane oxygenation
- patient reported outcomes
- coronary artery disease
- adverse drug
- men who have sex with men
- south africa
- acute respiratory distress syndrome
- respiratory failure
- mesenchymal stem cells
- rectal cancer